IMS Health — Jefferies 2016 Healthcare Conference
21 slides from IMS Health's conference presentation, Jun 6, 2016
Slide 1: Jefferies 2016 Healthcare Conference
Jefferies 2016 Healthcare Conference Tom Pike CEO June 7, 2016 NYSE: Q
Slide 2: Cautionary Statements Regarding Forward Looking Statements
Cautionary Statements Regarding Forward Looking Statements This communication contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.
Slide 3: Important Information About the Transaction and Where to Find It
Important Information About the Transaction and Where to Find It In connection with the proposed transaction, Quintiles has filed a registration statement on Form S-4 with the Securities and Exchange Commission (“SEC”) that includes the preliminary joint proxy statement of Quintiles and IMS Health a
Slide 4: Enterprise Vision and Strategy
Enterprise Vision and Strategy Quintiles Vision We bring people and knowledge together for a healthier world. Our Customer Promise Excellence at Global People, Process & Technology Scientific, Therapeutic & Rx Experience Quantitative & Analytical Expertise Biopharma Product Development Integrated He
Slide 5: Attractive and Growing Market
Attractive and Growing Market ~$200bn total market across both segments with increasing outsourcing penetration which drives estimated growth of 6% – 8% per year from 2015 – 2018 $97bn Product Development Market(2) $101bn Integrated Healthcare Services Market(2,3) Phase I-IV Clinical Development $97
Slide 6: Deep Therapeutic, Domain, & Regulatory Expertise Across Fast-Growing Therapy Areas
Deep Therapeutic, Domain, & Regulatory Expertise Across Fast-Growing Therapy Areas >10 sole-source relationships across large, mid, and small biopharma Helped develop or commercialize 98 of the top 100 best-selling products of 2014 All of Top 30 Oncology products All of Top 30 CNS products >1,000 on
Slide 7: Quintiles' Global Delivery Network Extends Our Industry Leadership Position
Quintiles’ Global Delivery Network (GDN) Extends Our Industry Leadership Position >5,100 Employees At 7 locations in 5 countries Centrally-managed For process consistency & standardization Operates as ‘one’ In a virtual, coordinated manner Strategically leverages our global presence… …and drives qua
Slide 8: Integrated Data Assets Combine Our Deep Expertise and Global Scale
Integrated Data Assets Combine Our Deep Expertise and Global Scale Data Integration is key to unlocking the productivity puzzle Quintiles Infosario® Data Factory Infosario Analytics Patient Data Real World Data Research Data Trial and Subject Data Patient Communities Electronic Health Records Access
Slide 9: Quintiles Infosario Platform
Quintiles Infosario® Platform Planning & Design Global Safety System Analytics & Informatics Genomics & Biomarkers Digital Patient Communities Clinicalresearch.com Mediguard.com “I Am More Than Lupus” 61mm Unique Patient Records (EHR) >24 Prime sites >1,200 Partner sites >298,000 Investigators ~100
Slide 10: Track Record of Profitable Growth and Consistency
Track Record of Profitable Growth and Consistency Long-term performance underpinned with a diversified customer portfolio See slide 17 for the reconciliation of net income to Adjusted EBITDA. Book-to-bill calculated as NNB divided by Service Revenues. As of March 31, 2015. $ Millions $ Millions $ Mi
Slide 11: Q1 2016 Financial Highlights
Q1 2016 Financial Highlights See appendix slide 18. See appendix slide 19. See appendix slide 20. 200bps Adjusted Income from Operations Margin Expansion(2) $1.03B Net New Business resulting in backlog of $12 billion Agreement to merge with IMS Health in all-stock transaction to create Quintiles IMS
Slide 12: Introducing Quintiles IMS
Introducing Global healthcare intelligence to measure and realize value from R&D and Commercial execution to real world patient outcomes Information-powered, technology-enabled, differentiated solutions to address life science’s most pressing issues
Slide 13: Two Best-in-Class Businesses
Two Best-in-Class Businesses 2015 Metrics Differentiated Resources Leading Capabilities Revenue: $4.3B Adj. EBITDA / Margin(1): $819M / 19% >1,100 medical doctors, ~1,050 PhDs, ~850 biostatisticians & statistical programmers Quintiles Infosario® platform: >298,000 clinical investigators, clinical re
Slide 14: Transformational Partner To Life Sciences
Transformational Partner To Life Sciences Game Changing Solutions Realize Greater R&D Efficiency Demonstrate Value & Measure Outcomes Maximize Commercial ROI Smarter CRO Real World Evidence & Connected Health Technology-Enabled Commercial Operations Equipping therapeutic, scientific, and domain expe
Slide 15: At Quintiles, we improve your probability of success
At Quintiles, we improve your probability of success
Slide 16: Appendix
Appendix O ouinTILes’ 16
Slide 17: Adjusted EBITDA Reconciliation
Adjusted EBITDA Reconciliation Adjusted EBITDA Reconciliation Year Ended December 31 LTM period ended (In Thousands) 2011 2012 2013 2014 2015 3/31/2016 Adjusted EBITDA: Net Income Attributable to Quintiles Transnational Holdings Inc. $241,772 $177,546 $226,591 $356,383 $387,205 $407,475 Interest Exp
Slide 18: 2016 Constant Currency Reconciliation
The exchange rate impacts on service revenues equals the current period service revenues at actual rates less the current period service revenues for foreign currency denominated contracts recalculated at the prior period exchange rates. The exchange rate impacts on expenses equals the current perio
Slide 19: Income Statement GAAP – Non-GAAP Reconciliation
1 Change in estimated fair value of contingent consideration on business combinations. 2 Reflects the portion of Q2 Solutions’ after-tax non-GAAP adjustments attributable to the minority interest partner. Note: Totals may not sum due to rounding; percentages are calculated from the actual results ro
Slide 20: Reconciliation of Net Income to Non-GAAP Adjusted Net Income and Diluted Adjusted EPS
Reconciliation of Net Income Attributable to Quintiles to Non-GAAP Adjusted Net Income and Diluted Adjusted EPS 1 EPS is represented in whole dollars. 2 Change in estimated fair value of contingent consideration on business combinations. 3 Reflects the portion of Q2 Solutions’ after-tax non-GAAP adj
Slide 21: IMS Health Net Income to Adjusted EBITDA
Stock-based compensation related charges are included in Operating costs of information, Direct and incremental costs of technology services and Selling and administrative expenses as follows: Restructuring and related charges includes severance and impairment charges and the cost of employee and th
IMS Health Holdings — Jefferies 2016 Healthcare Conference on 6ix